Prolonged drug-drug interaction between terbinafine and perphenazine

Psychiatry Investigation

Volumn 9, Issue 4, 2012, Pages 422-424

  Park, Young Min ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Akathisia; Drug drug interaction; Extrapyramidal symptoms; Perphenazine; Terbinafine

Indexed keywords

CLONAZEPAM; CYTOCHROME P450 2D6; MIRTAZAPINE; PERPHENAZINE; PROPRANOLOL; TERBINAFINE;

AKATHISIA; ANXIETY; ARTICLE; BARNES AKATHISIA SCALE; BRADYKINESIA; CASE REPORT; DEPRESSION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GAIT DISORDER; HAMILTON SCALE; HUMAN; INSOMNIA; NUCLEAR MAGNETIC RESONANCE IMAGING; SIMPSON-ANGUS SCALE; URINALYSIS; WEAKNESS;

EID: 84871568120     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2012.9.4.422     Document Type: Article

References (15)

1. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-180.
2. Levine B, Jenkins A, Chute D, Smialek JE. Perphenazine distribution in a postmortem case. J Anal Toxicol 1999;23:127-129.
3. Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit 2005; 27:680-682.
4. Schatz F, Brautigam M, Dobrowolski E, Effendy I, Haberl H, Mensing H, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995;20:377-383.
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
6. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
7. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
8. Faergemann J, Zehender H, Denouël J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol 1993;73:305-309.
9. Zehender F, Cabiac MD, Denouël J, Faergemann J, Donatsch P, Kutz K, et al. Elimination kinetics of terbinafine from human plasma and tissues following multiple dose administration and comparison with 3 main metabolites. Drug Invest 1994;8:203-210.
10. Kovarik JM, Mueller EA, Zehender H, Denouël J, Caplain H, Millerioux L. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother 1995;39: 2738-2741.
11. Dahl-Puustinen M-L, Lidén A, Alm C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989;46:78-81.
12. Venkatakrishnan K, Obach RS. In vitro-in vivo extrapolation of CY-P2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 2005; 33:845-852.
13. Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos 1999;27:770-775.
14. Molden E, Garcia BH, Braathen P, Eggen AE. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol 2005;61:119-125.
15. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-in-duced akathisia. A randomized, double-blind, placebo-and propranolol-controlled trial. Biol Psychiatry 2006;59:1071-1077.